Target intelligence / Profile preview

Cell cycle checkpoint control protein RAD9B (RAD9B)

Target
RAD9B
Molecular classification
DNA damage checkpoint protein, Exonuclease, Cell cycle checkpoint clamp component, Other
01

Overview

Cell cycle checkpoint control protein RAD9B (RAD9B) is a conserved DNA damage response protein implicated in cell cycle checkpoint control, DNA repair, apoptosis regulation, and embryonic neural development[1][2][3]. RAD9B acts as a component of the 9-1-1 checkpoint clamp, a heterotrimeric complex (with RAD1 and HUS1) that is loaded onto DNA at damage sites, analogous to the PCNA sliding clamp, and participates in recruiting repair and signaling factors[1][4]. Unlike its paralogue RAD9A, RAD9B is predominantly expressed in the testis and brain, has distinct nucleolar stress response signaling via ATR and JNK, modulates the timing of cell cycle progression in G1, and is vital for embryonic viability and proper neural tube morphogenesis[1][2][3]. Genetic aberrations in RAD9B are associated with increased sensitivity to certain genotoxic agents and implicated in neural tube defects and testicular tumorigenesis. No direct therapeutic agents currently target RAD9B, but its biomarker potential and fundamental role in genomic integrity make it of translational interest in oncology and developmental biology[1][2][3].

Other names
RAD9BCell cycle checkpoint control protein RAD9BhRAD9BFLJ40346DNA repair exonuclease rad9 homolog BRAD9 homolog B
02

Biological functions

Cell cycle checkpoint controlDNA repair and DNA damage responseApoptosis regulationResponse to nucleolar stressEmbryonic development and neural tube morphogenesis
03

Disease associations

Cancer (tumor suppressor role in testicular tumors/seminomas, possible role as oncogene/tumor suppressor in other cancers by analogy to RAD9A)Neurodevelopmental disordersNeurodegenerative disease
04

Safety considerations

Embryonic lethality if fully knocked outNeural development impairment with loss-of-function mutationsPotential cancer risk from loss of tumor suppressor functionNo direct safety concerns for drugs, as no drugs target RAD9B.
05

Biomarkers

Reduced RAD9B expression in testicular germ cell tumors/seminomasAberrant RAD9B function as a risk factor in neural tube defectsChanged RAD9B expression in Parkinson’s disease animal models

Beyond the preview

Go deeper on Cell cycle checkpoint control protein RAD9B (RAD9B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cell cycle checkpoint control protein RAD9B (RAD9B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call